Home / VEGFR2/KDR/Flk-1 / Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein

Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein

Catalog #: 443-KD
10 Citations Datasheet

Carrier Free

Catalog # Availability Size / Price Qty
443-KD-050/CF

With Carrier

Catalog # Availability Size / Price Qty
443-KD-050
R&D Systems Recombinant Proteins and Enzymes
1 Image
Product Details
Citations (10)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein Summary

Product Specifications

Purity
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its ability to inhibit the VEGF-dependent proliferation of HUVEC human umbilical vein endothelial cells. The ED50 for this effect is 10-30 ng/mL in the presence of 5 ng/mL recombinant mouse VEGF.
Source
Mouse myeloma cell line, NS0-derived mouse VEGFR2/KDR/Flk-1 protein
Mouse VEGFR2
(Ala20-Glu762)
Accession # P35918		 IEGRMD Human IgG1
(Pro100-Lys330)		 6-His tag
N-terminus C-terminus
Accession #
P35918
N-terminal Sequence
Analysis
Ala20
Structure / Form
Disulfide-linked homodimer
Predicted Molecular Mass
110 kDa (monomer)
SDS-PAGE
166-191 kDa, reducing conditions

Product Datasheets

You must select a language.

x

443-KD (with carrier)

Product Datasheet

You must select a language.

x

443-KD/CF (carrier free)

Product Datasheet

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

443-KD

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 50 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

443-KD/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: VEGFR2/KDR/Flk-1

VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.

Mouse VEGFR2 cDNA encodes a 1367 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 743 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 583 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity. The recombinant soluble VEGFR2 Fc Chimera binds VEGF with high affinity and is a potent VEGF antagonist.

References
  1. Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
  2. Achen, M.G. et al. (1998) Proc. Natl. Acad. Sci. USA. 95:548.
Long Name
Vascular Endothelial Growth Factor Receptor 2
Entrez Gene IDs
3791 (Human); 16542 (Mouse)
Alternate Names
CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2

Citations for Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

10 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Dual Targeting of Endothelial and Cancer Cells Potentiates In Vitro Nanobody-Targeted Photodynamic Therapy
    Authors: V Mashayekhi, KT Xenaki, PMP van Bergen, S Oliveira
    Cancers, 2020-09-23;12(10):.
    Species: Llama
    Sample Types: In Vivo
    Applications: Bioassay
  2. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold
    Authors: K Fujiwara, A Tsunei, H Kusabuka, E Ogaki, M Tachibana, N Okada
    Cells, 2020-05-09;9(5):.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Extracellular Protein Fibulin-7 and Its C-Terminal Fragment Have In Vivo Antiangiogenic Activity
    Authors: T Ikeuchi, S de Vega, P Forcinito, AD Doyle, J Amaral, IR Rodriguez, E Arikawa-Hi, Y Yamada
    Sci Rep, 2018-12-05;8(1):17654.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  4. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research
    Authors: Naoki Okada
    Mol Ther Oncolytics, 2016-11-16;3(0):16024.
    Species: Mouse
    Sample Types: Complex Sample Type
    Applications: Bioassay
  5. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity.
    Authors: Fleetwood F, Klint S, Hanze M, Gunneriusson E, Frejd F, Stahl S, Lofblom J
    Sci Rep, 2014-12-17;4(0):7518.
    Applications: Bioassay
  6. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.
    Authors: Wuest TR, Carr DJ
    J. Exp. Med., 2009-12-21;207(1):101-15, S1-2.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  7. Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1.
    Authors: Ponticelli S, Marasco D, Tarallo V, Albuquerque RJ, Mitola S, Takeda A, Stassen JM, Presta M, Ambati J, Ruvo M, De Falco S
    J. Biol. Chem., 2008-10-15;283(49):34250-9.
    Species: Mouse
    Sample Types: Peptide
    Applications: Binding Assay
  8. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro.
    Authors: Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, Wang J, Ling V, Sun L
    Chem. Biol., 2006-05-01;13(5):549-56.
    Species: Human
    Sample Types: Recombinant Protein
    Applications: Surface Plasmon Resonance
  9. Increased VEGF levels induced by anti-VEGF treatment are independent of tumor burden in colorectal carcinomas in mice.
    Authors: Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschluter M, Strehl J, Rabe C, Sauerbruch T, Prieto J, Caselmann WH, Qian C
    Gene Ther., 2006-04-13;13(16):1198-205.
    Applications: Western Blot
  10. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
    Authors: Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J, Qian C, Caselmann WH, Schmitz V
    Hepatology, 2005-06-01;41(6):1233-40.
    Applications: Western Blot

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein

There are currently no reviews for this product. Be the first to review Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein and earn rewards!

Have you used Recombinant Mouse VEGFR2/Flk-1 Fc Chimera Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review